ArticleFuture oncology (London, England)2012
Elevated levels of HSF1 indicate a poor prognosis in breast cancer.
Article in Future oncology (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- Inhibition of Heat Shock Factor 1 Signaling Decreases Hepatoblastoma Growth via Induction of Apoptosis.The American journal of pathology · 2023Article
- Receptor-Interacting Protein 140 Enhanced Temozolomide-Induced Cellular Apoptosis Through Regulation of E2F1 in Human Glioma Cell Lines.Neuromolecular medicine · 2022Article
- Proteomics analysis of proteins interacting with heat shock factor 1 in squamous cell carcinoma of the cervix.Oncology letters · 2019Article
- FAM3C-YY1 axis is essential for TGFβ-promoted proliferation and migration of human breast cancer MDA-MB-231 cells via the activation of HSF1.Journal of cellular and molecular medicine · 2019Article
- Phenethyl Isothiocyanate, a Dual Activator of Transcription Factors NRF2 and HSF1.Molecular nutrition & food research · 2018Review
- Discovering a Reliable Heat-Shock Factor-1 Inhibitor to Treat Human Cancers:Frontiers in oncology · 2018Article
- Defective heat shock factor 1 inhibits the growth of fibrosarcoma derived from simian virus 40/T antigen‑transformed MEF cells.Molecular medicine reports · 2015Article
- Higher heat shock factor 1 expression in tumor stroma predicts poor prognosis in esophageal squamous cell carcinoma patients.Journal of translational medicine · 2015Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
HSF1 is the transcriptional activator of heat shock protein genes in both cell stress and cancer. The studies of Santagata et al. clearly establish that HSF1 levels are increased in the nuclei of mammary cancer cells, both at the in situ and invasive stages, and that these levels are closely correlated with increased mortality. HSF1 levels were elevated in estrogen receptor-positive cells, as well as HER2-expressing and triple-negative breast cancer cells, and higher levels of nuclear HSF1 were associated with a poor prognosis. These studies establish a clear role for HSF1 in human mammary carcinoma and suggest the potential for targeting HSF1 in breast cancer treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.